Eupraxia hits enrollment target in Phase 2b EoE trial, sets December readout
The company completed enrollment of 120 patients in the placebo-controlled portion of its RESOLVE trial and expects interim results in December 2026, with cash guided into the second half of 2028.
SEC filing